The introduction of the Stelo by Dexcom and Lingo by Abbott at CES 2025 represents a significant advancement in healthcare technology, offering accessible and affordable glucose monitoring for various users.
Dexcom's Stelo is tailored specifically for Type 2 diabetes management, providing continuous glucose tracking and real-time data via an app, which could transform diabetes care for many users.
On the other hand, Abbott's Lingo focuses on general wellness, helping users track glucose for healthier lifestyle choices, thus broadening the appeal of CGM technology beyond diabetes.
With prices starting at $50 for Lingo and $90 for Stelo, both devices aim to make continuous glucose monitoring widely accessible, breaking barriers of cost and insurance.
Collection
[
|
...
]